Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.58 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.58 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119995 | 0.81 | RXFP1 (0.70) | MEN1KMT2AGPR27AVPR2SLC20A2 | |
| SCHEMBL5115424 | 0.81 | SLC20A2 (0.66) | MEN1KMT2ALMNATP53POLB | |
| SCHEMBL15647630 | 0.81 | IDH1 (1.00) | IDH1 | |
| SCHEMBL30926865 | 0.80 | GPR27 (0.61) | IDH1MEN1KMT2AMAPTGPR27 | |
| SCHEMBL27180015 | 0.80 | GPR27 (0.61) | IDH1MEN1KMT2AMAPTGPR27 | |
| SCHEMBL27181381 | 0.80 | RHOC (0.65) | MEN1KMT2ALMNATP53POLB | |
| SCHEMBL15840630 | 0.79 | MAPT (0.68) | IDH1MEN1KMT2ALMNATP53 | |
| SCHEMBL26657642 | 0.78 | IDH1 (0.67) | IDH1MEN1KMT2ACNR2 | |
| SCHEMBL7572556 | 0.78 | PGR (0.67) | IDH1MEN1KMT2AMAPTSLC20A2 | |
| SCHEMBL5117189 | 0.77 | SLC10A6 (0.72) | MEN1KMT2ALMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | IDH1 365/4885MEN1 2307/4885KMT2A 3637/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | IDH1 365/4885MEN1 2307/4885KMT2A 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.